Business Description
Amplia Therapeutics Ltd
ISIN : AU0000023822
Description
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 81.68 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.9 | |||||
3-Year EPS without NRI Growth Rate | 19.8 | |||||
3-Year FCF Growth Rate | 9.9 | |||||
3-Year Book Growth Rate | -0.4 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.46 | |||||
9-Day RSI | 44.7 | |||||
14-Day RSI | 46.39 | |||||
3-1 Month Momentum % | -11.54 | |||||
6-1 Month Momentum % | 15 | |||||
12-1 Month Momentum % | -32.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 19.79 | |||||
Quick Ratio | 19.79 | |||||
Cash Ratio | 16.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.1 | |||||
Shareholder Yield % | -36.68 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -22.36 | |||||
ROA % | -21.23 | |||||
ROIC % | -107.92 | |||||
3-Year ROIIC % | -335 | |||||
ROC (Joel Greenblatt) % | -354.21 | |||||
ROCE % | -22.17 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.5 | |||||
Price-to-Tangible-Book | 1.8 | |||||
EV-to-EBIT | -4.9 | |||||
EV-to-EBITDA | -4.96 | |||||
EV-to-FCF | -4.39 | |||||
| Price-to-Net-Current-Asset-Value | 1.8 | |||||
| Price-to-Net-Cash | 2.25 | |||||
Earnings Yield (Greenblatt) % | -20.41 | |||||
FCF Yield % | -13.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:INNMF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amplia Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.011 | ||
| Beta | -3.0204 | ||
| 3-Year Sharpe Ratio | 0.74 | ||
| 3-Year Sortino Ratio | 2.62 | ||
| Volatility % | 233.05 | ||
| 14-Day RSI | 46.39 | ||
| 14-Day ATR ($) | 0.008225 | ||
| 20-Day SMA ($) | 0.099245 | ||
| 12-1 Month Momentum % | -32.67 | ||
| 52-Week Range ($) | 0.0492 - 0.27 | ||
| Shares Outstanding (Mil) | 513.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amplia Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amplia Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Amplia Therapeutics Ltd Frequently Asked Questions
What is Amplia Therapeutics Ltd(INNMF)'s stock price today?
The current price of INNMF is $0.09. The 52 week high of INNMF is $0.27 and 52 week low is $0.05.
When is next earnings date of Amplia Therapeutics Ltd(INNMF)?
The next earnings date of Amplia Therapeutics Ltd(INNMF) is .
Does Amplia Therapeutics Ltd(INNMF) pay dividends? If so, how much?
Amplia Therapeutics Ltd(INNMF) does not pay dividend.
Guru Commentaries on OTCPK:INNMF
No articles.
Press Release
Articles on Amplia Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers